Scientists have developed a new version of a medication, first isolated from the saliva of sea snails, that could be taken in pill form to relieve the most severe forms of pain as effectively as morphine but without risking addiction.

Academics at Northumbria University have demonstrated a link between teenage binge drinking and damage to prospective memory.

Patients who undergo epidural or spinal anesthesia instead of general anesthesia have lesser chances of developing infections at the sites of total hip or knee replacements , reported a new study conducted in Taiwan. The study said while the risk of infection is small, the potential for problems is significant.

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of PatentExplorer, an interdisciplinary software tool for assessing the patent situation of novel biomolecules and targets.

"Many people," says Dr. Eeva Karjalainen, of the Finnish Forest Research Institute, Metla, "feel relaxed and good when they are out in nature. But not many of us know that there is also scientific evidence about the healing effects of nature."

US researchers have developed a promising new technique that might one day enable doctors to regrow broken or diseased joints in patients.

Teva Respiratory, a US-based respiratory subsidiary of Teva Pharmaceutical, has said that its hydrofluoroalkane (HFA) nasal aerosol Phase III seasonal allergic rhinitis (SAR) trial met both the primary and secondary endpoints which showed clinical efficacy in patients with SAR versus placebo.

Abraxis BioScience granted exclusive marketing rights to Specialised Therapeutics for ABRAXANE in New Zealand. Specialised Therapeutics will commence distribution upon receiving reimbursement approval of ABRAXANE from the New Zealand pharmaceutical reimbursement authority, Pharmac.

Devax, Inc. announced today the company received CE (Conformité Européenne) Mark for its AXXESS™ Biolimus A9® Eluting Coronary Bifurcation Stent System (AXXESS System), allowing the company to initiate sales in the European Union and other countries that recognize the CE Mark.

Why some obese people go on to become diabetic while others do not. It is common to find obese people – even morbidly obese people – who are healthier than their condition would normally allow.

Researchers have collected venom from octopuses in Antarctica for the first time, significantly advancing our understanding of the properties of venom as a potential resource for drug development.

Antares Pharma has said that its Anturol gel met its primary endpoint of reduction in urinary incontinence episodes for both doses studied (56mg daily or 84mg daily) in a Phase 3 study evaluating patients with overactive bladder (OAB).

Stellar Pharmaceuticals Inc.a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced today that it has now been issued patents ("the patents") that are central to one of its lead products, Uracyst(R)

Merck KGaA announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).

Merck KGaA announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).

Drinking alcohol can not only ease the symptoms of rheumatoid arthritis it appears to reduce disease severity too, research suggests.

A new predictive marker which could help doctors to decide whether breast cancer patients would benefit from chemotherapy has been identified by a team of scientists.

GW Pharmaceuticals Plc's cannabis-derived medicine Sativex has been approved in its second European market, Spain, as an add-on therapy for treating spasticity in patients with multiple sclerosis (MS).

Illumina has established a new network initiative designed to link scientists looking to undertake large-scale whole human genome sequencing projects with the establishments that can carry them out.

　Since July 2006, Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, “Chugai”)] has shown videos with easy-to-understand explanations on medicine, biotechnology, and cancer at the permanent exhibit "Dr. Kitanomaru's Bio Pharmaceutical Laboratory" at the Science Museum (Chiyoda-ku, Tokyo).